The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis
CONCLUSION: Response to PCSK9i was minimal in this cohort of patients with HoFH. No patients achieved EAS LDL-C targets, and most failed to reach the EAS-recommended 15% LDL-C reduction for PCSK9i therapy continuation. These results suggest additional LLTs are necessary to achieve LDL-C targets in HoFH.PMID:38169062 | DOI:10.1007/s12325-023-02764-y
Source: Adv Data - Category: Epidemiology Authors: Awad Alshahrani Naji Kholaif Mutaz Al-Khnifsawi Hawazen Zarif Moeber Mahzari Source Type: research
More News: African Health | Cholesterol | Epidemiology | Middle East Health | Statin Therapy | Vytorin | Zetia